ALRX, SLAT, DUSS, NVSR, LVLV, ACCP, WDRP, SOMX, PVRE, LLBO, OOGI
OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, July 23rd
Our Stocks to Watch today include AlphaRx Inc. (OTCBB: ALRX), Superlattice Power Inc. (OTCBB: SLAT), Dussault Apparel Inc. (OTCBB: DUSS), NavStar Technologies Inc. (OTC: NVSR), LEVEL Vision Electronics Ltd. (OTC: LVLV), Access Pharmaceuticals Inc. (OTCBB: ACCP), Wanderport Corp. (OTC: WDRP), Somaxon Pharmaceuticals Inc. (Nasdaq: SOMX), Pavilion Energy Resources Inc. (OTC: PVRE), Lifeline Biotechnologies Inc. (OTC: LLBO) and Odyssey Oil & Energy Inc. (OTCBB: OOGI).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
ALPHARX INCORPORATED (OTCBB: ALRX)
"Up 38.61% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ALRX.php
Company Profile: http://www.otcpicks.com/alpharx/alpharx.htm
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.
ALRX News:
July 23 - AlphaRx Presents Positive Preclinical Data on Zysolin™ Inhalable Nanoparticles at Controlled Release Society Annual Meeting
AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results which demonstrated that an inhaled tobramycin nanoparticle (Zysolin) formulation was a more effective treatment in animal models of acute Pseudomonas aeruginosa pneumonia when compared to inhaled and injected conventional tobramycin solutions. The data was presented recently in an oral podium session at the 36th Annual Meeting and Exposition of the Controlled Release Society in
"These are very encouraging results, as they suggest that Zysolin employed in this route of administration may be more effective, providing significant advantages over conventional drug formulations," stated Joseph Schwarz, Ph.D., Chief Scientist of AlphaRx. "We believe that building on this data, additional research will lead us toward the development of a drug that targets and eradicates intracellular pathogens, which to date, have proven to be very difficult to treat clinically."
The study results demonstrate that Zysolin is significantly efficacious in acute pneumonia animal models induced by gram negative pathogens including P. aeruginosa. In these lethality-based studies, Zysolin consistently increased survival rate to 50% over a Tobramycin treatment group, wherein all untreated animals died within 24 hours after infection. P. aeruginosa is one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, being directly responsible for death rates approaching 40%. This data suggests that the nanoparticulate formulation of Zysolin may utilize a unique mechanism of action differentiating it from conventional formulations, enhancing antimicrobial activity against gram negative pathogens. Zysolin has the potential to be a first-in-class anti-infective nanomedicine.
The Controlled Release Society (CRS) is an international organization consisting of 3,000 members from more than fifty countries. Two-thirds of CRS membership are from the pharmaceutical industry and one-third consist of academic and government members. The CRS is the premier multidisciplinary society dedicated to the promotion of the science, technology, and innovative delivery of bio-actives for the benefit of the society.
ABOUT ZYSOLIN™
Zysolin is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin improves the intracellular activity of Tobramycin — in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin, Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.
SUPERLATTICE POWER INCORPORATED (OTCBB: SLAT)
"Up 4.62% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SLAT.php
Company Profile: http://www.otcpicks.com/superlattice-power.htm
Superlattice Power, Inc. was incorporated in
SLAT News:
July 14 - Superlattice Power Inc. Research Group Successfully Implemented a Battery Thermal Management System Designed to Protect
Superlattice Power Inc. (OTCBB: SLAT), emerging leader in the development and marketing of next generation lithium-powered batteries worldwide, proudly announces a fully automatic thermal management system to drive electric vehicles powered by lithium ion polymer batteries under extreme weather conditions.
Using 29.6 kilowatt hours of lithium ion battery the researchers of SLAT investigated the factors and range of operating temperatures affecting lithium ion battery performance.
The thermal management system will control the temperature of battery pack and electric vehicle can safely be used in regions with extreme climate temperature ranging from –30 degrees C to +60 degrees C. The newly developed thermal management system will maintain battery temperature within the range of 15 degrees C to 25 degrees C during driving and parking. Safety and battery performance issues related to high/low temperature will be controlled by this new thermal management package.
It has been recommended by all lithium ion battery manufacturers that the efficiency of battery decreases significantly and it is also unsafe when used at subzero temperature. Similarly, it is unsafe to use battery pack or charge when the temperature is above 60 degrees C.
The objective of Superlattice Power Inc. is to manufacture and develop the safe rechargeable lithium ion batteries for onboard energy storage in HEVs and EVs. The technical success of the company is insured by its proprietary battery module design, battery cell management systems, charging algorithm and battery thermal management system. Superlattice Power has a team well trained in lithium ion battery technology and has received support from different manufacturers worldwide.
DUSSAULT APPAREL INCORPORATED (OTCBB: DUSS)
"Up 11.67% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/DUSS.php
Company Profile: http://www.otcpicks.com/dussault-apparel.htm
Dussault Apparel, Inc. is a designer, manufacturer, wholesaler and retailer of high-end quality apparel, its expanding product line includes custom designed hoodies, jeans, jewelry, t-shirts, hats and leather goods. An accelerated growth company, Dussault Apparel, Inc. trades on the Nasdaq OTC bulletin board.
DUSS News:
July 20 - Dussault Apparel Inc. Signs Agreement With Canadian Distributor EHM Holdings
Dussault Apparel Inc. (OTCBB: DUSS) (the Company) announced that its moderately priced lifestyle brand Deuce by Dussault will be distributed in Canada by EHM Holdings based in Vancouver, BC, the company is one of the leading distributors in the territory representing brands such as DKNY, Mexx, True Religion Mynk and many more. EHM Holdings plans to introduce Deuce by Dussault to the Canadian market in the late summer, fall of 2009.
"As we continue to develop the Dussault brand, we are very pleased to be working with Ted Margulius and his team at EHM Holdings for distribution of the Deuce Collection.
"We are very excited about our association with Dussault Apparel. The people are great and it's such a cool and unique brand, I think the public will embrace it," said Ted Margulius of EHM Holdings.
NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR)
"Up 8.04% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/NVSR.php
Company Profile: http://www.otcpicks.com/navstar-technologies/navstar-technologies.htm
NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider.
NVSR News:
July 22 - Vehicle/Asset Tracking Forecast to Grow From $3.0B to $5.0B by 2011
NavStar Technologies, Inc. (OTC: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo with specific geographic focus in Latin America, has made available to shareholders and investors an independent research report on Vehicle/Asset tracking and monitoring.
According to the report, adoption of vehicle/asset tracking and monitoring is likely to be driven by factors such as:
* Increased recognition of tracking/monitoring benefits
* Worker productivity
* Administrative efficiency
* Reliable and affordable data communications
* Increase availability of wireless coverage
The report says that today only 10% of the 20M fleet vehicles in the
N. Douglas Pritt, Chairman and CEO, confirmed that NavStar's business model for sales into
NavStar also re-affirmed guidance regarding its expected financial performance over the next 5 years. The successful achievement of these financial objectives assumes the company's procurement of up to $2.0 million of funding in the 3rd quarter of this year and the completion of the services/software company.
N. Douglas Pritt, Chairman and CEO, said, "We continue to stay focused on getting POs from our distribution partners in
For the complete research report, go to www.navstarinc.com and click the "What's New" link.
LEVEL VISION ELECTRONICS LTD. (OTC: LVLV)
Detailed Quote: http://www.otcpicks.com/quotes/LVLV.php
Company Profile: http://www.otcpicks.com/level-vision-electronics/level-vision-electronics.htm
LEVEL Vision Electronics is an ODM/OEM (designer and manufacturer) of consumer electronics (mainly Wireless Handsets) primarily concentrating on the world's emerging markets. Through its Unique Business Model, LEVEL works hand-in-hand with the Telcos to customize the products to their specific targeted market requirements. Our current 3D products can be found online at www.levelelectronics.com and our upcoming related wireless handset software products are currently under development.
LVLV News:
July 21 - LEVEL Upgrading Its Website With Investor Aimed Information
LEVEL Vision Electronics Ltd. (OTC: LVLV) announced that it is currently putting final touches on its newly re-designed Website to keep Investors and the public informed of current Information, weekly News and New Product updates.
The new design is in line with LEVEL's plans to reach out to the public and inform shareholders and prospective investors on the company's roadmap. The following is a brief description of what will be available on the website; Stock quotes, Management & Board of Directors' resumes, current Product line, General and Specific Information about the company and much more. The official website address, as well as its "Go Live" date, will be released in an upcoming press release.
"With heavy requests for more information about the company coming in via our current website, we felt it timely to design a new and updated site which will allow the public to view and read all current information and public news. The Company information will now be available in one convenient place with a fresh new look," said Habib Coriaty, President and CEO of Level Vision Electronics Ltd. "In addition to the recent announcement of our new Corporate Finance Advisors, Hilbroy Advisory Inc., we are reaching out to the world's markets with information aimed at current shareholders and prospective investors," added Mr. Jean-Francois Lefebvre, Vice President of LEVEL Vision Electronics Ltd.
ACCESS PHARMACEUTICALS INCORPORATED (OTCBB: ACCP)
"Up 35.27% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ACCP.php
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.
ACCP News:
July 23 - MuGard Data From
Prevention of Oral Mucositis Expands Market Potential to Multiple Billions Of Dollars
Access Pharmaceuticals, Inc. (OTCBB: ACCP), announced that its European partner, SpePharm, is collecting data from a post approval study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK showing prevention of oral mucositis. In a multi-center study expected to enroll a total of 280 patients, patients are provided with seven weeks of MuGard therapy, and begin using MuGard one week prior to radiation treatment and then throughout the subsequent six weeks of planned therapy. The first 140 patients being treated in this assessment study have been enrolled and treated, and as of the time of the update, none of these patients have experienced any oral mucositis.
"The initial feedback from SpePharm on their experience in the
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, used prophylactically for patients undergoing chemotherapy and radiation therapy, is estimated to be in excess of $5 billion world-wide.
MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.
WANDERPORT CORPORATION (OTC: WDRP)
"Up 122.22% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/WDRP.php
Wanderport Corporation is a holding and business development company specializing in the investment and deployment of environmentally friendly technology such as, primary alternative renewable energy and energy saving products like electric vehicles which reduce global dependence on oil.
WDRP News:
July 22 - Wanderport Signs a Definitive Agreement to Acquire the Exclusive Rights to Pulsar Revolutionary Water Heater Technology
Wanderport Corp. (OTC: WDRP) announced that it has concluded a definitive agreement with the founder and holder of the intellectual property and trademark of Pulsar Advanced Technologies for the acquisition of the exclusive global sales and marketing, licensing and distribution rights to Pulsar's TIPTA award winning tank-less hot water heater technology.
Wanderport's substantial investment to acquire Pulsar's intellectual property, trademark and worldwide rights enables Wanderport to achieve the company's "Growth by Green" business model. "It is a natural synergy making Wanderport poised to become a global innovator in the billion dollar water heater industry," said Mr. Barry Somervail, President and CEO of Wanderport. Mr. Somervail continued by saying, "The acquisition is a clear indication to shareholders that Wanderport now has its own product which increases the company's financial position based on market cap, whilst potentially revolutionizing an industry with its solution that saves clean drinking water and greatly decreases energy consumption."
"I am very pleased to be working with Wanderport whose 'Green' business model will take full advantage of Pulsar's environmental benefits. I am very optimistic that our association will permit us to further develop the product and to bring to market and develop strong sales of Pulsar units locally and internationally," said Mr. Robert Simoneau, Founder of Pulsar Advanced Technologies. "Pulsar's energy efficient, continuous and on demand electric technology is based on microwave energy providing a continuous supply of heated water and fills a market niche that has not yet been converted to more efficient and environmentally friendly 'Green' tank-less methods or products," further added Mr. Simoneau.
Pulsar Advanced Technologies was the proud recipient of the 2005 TIPTA award (TCA; Toronto Construction association, Innovative Product and Technology Award), recognizing excellence in innovation in product or technology development, or its application.
SOMAXON PHARMACEUTICALS INCORPORATED (NASDAQ: SOMX)
"Up 111.26% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SOMX.php
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. A New Drug Application (NDA) for Silenor® (doxepin), Somaxon’s drug candidate for insomnia, has been filed with the U.S. Food and Drug Administration and currently is under review.
SOMX News:
July 8 - Somaxon Pharmaceuticals Completes $6 Million Private Equity Financing
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today said it has completed its previously announced private placement of approximately 5.1 million shares of its common stock at a price of $1.05 per share and seven-year warrants to purchase up to approximately 5.1 million additional shares of its common stock, exercisable in cash or by net exercise at a price of $1.155 per share, for aggregate gross proceeds of approximately $6 million. The price paid for the common stock is equal to the consolidated closing bid price on the Nasdaq Capital Market on the day of pricing, July 2, 2009.
The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and were sold in a private placement pursuant to Regulation D of the Securities Act. The securities may not be offered or sold in the
PAVILION ENERGY RESOURCES INCORPORATED (OTC: PVRE)
"Up 31.82% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PVRE.php
Pavilion Energy Resources, Inc., an energy resource company, engages in the acquisition, exploration, and drilling of oil and natural gas reserves in the mid-continent and gulf coast regions of the continental United States. The company was formerly known as Energetics Holdings, Inc. Pavilion Energy Resources is based in
PVRE News:
July 23 - Pavilion Energy Resources, Inc. Gas Wells Acquisition
Pavilion Energy Resources, Inc. (OTC: PVRE) (the "Company") announced that it has signed a Letter of Intent with Leland Energy, Inc., a private oil & gas development company to acquire Working Interests in 13 natural gas wells in Fentress county, Tennessee. These wells, which were all drilled in late 2006 & 2007, are low pressure, long life gas wells with 2 separate engineering Reserve Reports that show over 8.5 BCF in recoverable reserves. The transaction will be an "all stock" acquisition and is subject to the approval of the Board of Directors and the Partners of both companies. The company expects to bring the wells back online and commence generating income in the next quarter.
This is another step in the progress of building an operating energy resource company and adding value for PVRE shareholders.
The Company's goal is to achieve short-term profitability from acquiring and producing onshore, quality natural gas, light and heavy oil properties that are either cashflow positive or near cashflow positive.
LIFELINE BIOTECHNOLOGIES INCORPORATED (OTC: LLBO)
"Up 86.57% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/LLBO.php
Lifeline Biotechnologies, Inc. operates as a medical technology company in the
LLBO News:
July 8 - Lifeline Biotechnologies' Subsidiary, First Warning Systems, Completes Private Placement
Lifeline Biotechnologies, Inc. (OTC: LLBO) announced that its First Warning Systems™ subsidiary completed a Series A private placement of $125,000.
Jim Holmes, Lifeline’s CEO, said that “Lifeline’s subsidiary, First Warning Systems, Inc., has completed a private placement of promissory notes in the amount of $125,000. The promissory notes, due in mid-2010, are convertible into common stock of First Warning Systems, Inc. This initial funding has provided us with important resources needed to move forward on our expected FDA filings. While this funding was essential, we are preparing for the next round, a Series B private placement of common stock for up to $1,500,000. This amount should see us through the FDA process and clearance. With clearance by the FDA, we would expect to be ready for the process of market introduction of the First Warning System™.”
Holmes said, “First Warning Systems, Inc., has retained a firm specialized in FDA filings to assist in the preparation of its preliminary filing with the FDA. We expect the filing to be completed this month. The FDA’s response to this initial filing could take several months to receive. We expect the FDA’s response to give us guidance for the subsequent filing required in order to obtain marketing clearance for this proprietary process.”
Lifeline Biotechnologies has in the past year filed for a patent on the recent technological advancements of the First Warning System™, which has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is a well-known fact that mammograms are missing an estimated 20% to 30% of the breast cancers.
ODYSSEY OIL & ENERGY INCORPORATED (OTCBB: OOGI)
"Up 8.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/OOGI.php
Odyssey Oil & Energy Inc. is a green technology company with two separate operating entities: carbon sequestration and advanced battery technology. These initiatives take the form of two operating entities called ALG Bio Oil Ltd and H-Power (PTY) Ltd.
OOGI News:
July 8 - H-Power Enters Into Negotiations With An International Wind Energy Company
Odyssey Oil & Energy, Inc. (OTCBB: OOGI) announces H-Power International (Pty) Ltd, 51% owned by Odyssey, has entered into negotiations with a major international wind energy company to utilize H-Power's patented Hybrid Battery Technology to store the power generated by the wind farms.
Once the power has been stored using the patented technology it can be used at anytime for distribution into an electricity grid. This revolutionary technology allows for the storage of alternative green energy including solar and wind power. Power storage has been a major obstacle for solar and wind energy producers for some time.
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has been compensated seven thousand five hundred dollars by a third party (Blue Wave Advisors) for ALRX advertising and promotional services. OTCPicks.com has been previously compensated two thousand five hundred dollars by a third party (Blue Wave Advisors) for SLAT advertising and promotional services. OTCPicks.com has been recently compensated two thousand five hundred dollars by a third party (Blue Wave Advisors) for the current SLAT advertising and promotional campaign. OTCPicks.com has been compensated two thousand five hundred dollars by a third party (BlueWave Advisors) for DUSS advertising and promotional services. Previously OTCPicks.com has been compensated two thousand dollars by a third party (Planning Media) for DUSS advertising and promotional services. OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services. OTCPicks.com has been compensated three hundred thousand free trading shares from a third party (Cap Inc.) for LVLV advertising and promotional services. OTCPicks has been compensated three thousand five hundred dollars by a third party for ACCP advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
